Fig. 1
From: Trans-activation-based risk assessment of BRCA1 BRCT variants with unknown clinical significance
A schematic representation of the trans-activation assay (TA assay). Variant plasmid pcDNA3 GAL4 DBD:BRCA1(aa 1396–1863) is co-transfected with reporter plasmids pGAL4-e1b-Luc and phRG-TK into mammalian cells. Expression of the variant plasmid creates fusion proteins with GAL4 DBD and the BRCA1 BRCT-domains, which bind to the GAL4-specific promoter on the pGAL4-e1b-Luc reporter plasmid and induce expression of Firefly luciferase, in the absence of deleterious variants. The phRG-TK reporter plasmid functions as an internal control